8 terminated. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Terminated 8 |
| Phase 2 | 1 | Terminated 1 |
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. Efgartigimod PH20 SC, Placebo PH20 SC - Thyroid Eye Disease | Phase 3 | Terminated | argenx | 105 | 2024-03-28 | 2026-03-16 |
| A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease Efgartigimod PH20 SC, Placebo PH20 SC - Thyroid Eye Disease | Phase 3 | Terminated | argenx | 102 | 2024-03-27 | 2026-03-16 |
| Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease Observational cohort study, Batoclimab - Thyroid Eye Disease | Phase 3 | Terminated | Immunovant Sciences GmbH | 109 | 2022-11-06 | 2026-04-29 |
| A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) Secukinumab, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 3 | Terminated | Novartis Pharmaceuticals | 28 | 2021-11-29 | 2026-04-15 |
| Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules Radiofrequency ablation, Radioactive iodine - Thyroid Nodule, Toxic or With Hyperthyroidism, Autonomous Thyroid Function | Phase 3 | Terminated | Rijnstate Hospital | 40 | 2021-11-17 | 2025-07-17 |
| Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy? SSKI- Potassium Iodide - Graves Disease | Phase 3 | Terminated | Columbia University | 29 | 2015-02-10 | 2024-09-19 |
| Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care Placebo, Eprotirome - Heterozygous Familial Hypercholesterolaemia | Phase 3 | Terminated | Karo Bio AB | 236 | 2011-10-01 | 2012-09-03 |
| Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer CA4P, paclitaxel, carboplatin - Anaplastic Thyroid Cancer | Phase 2 / Phase 3 | Terminated | Mateon Therapeutics | 80 | 2007-08-01 | 2014-06-09 |
Graves Ophthalmopathy (4) · Autoimmune Diseases (1) · Coronary Artery Disease (1) · Dyslipidemias (1) · Exophthalmos (1) · Graves Disease (1) · Hypercholesterolemia (1) · Hyperthyroidism (1) · Thyroid Carcinoma, Anaplastic (1) · Thyroid Neoplasms (1) · Thyroid Nodule (1)
Endocrine System Diseases (8) · Eye Diseases (5) · Goiter (5) · Hyperthyroidism (5) · Immune System Diseases (5) · Orbital Diseases (5) · Autoimmune Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Exophthalmos (4) · Eye Diseases, Hereditary (4) · Genetic Diseases, Inborn (4) · Graves Disease (4) · Endocrine Gland Neoplasms (2) · Head and Neck Neoplasms (2)
3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid (1) · Carboplatin (1) · Iodine-131 (1) · Paclitaxel (1) · Potassium Iodide (1) · Radiofrequency Ablation (1) · Transurethral Resection of Prostate (1) · combretastatin (1) · fosbretabulin (1) · secukinumab (1)
argenx (2) · Columbia University (1) · Immunovant Sciences GmbH (1) · Karo Bio AB (1) · Mateon Therapeutics (1) · Novartis Pharmaceuticals (1) · Rijnstate Hospital (1)
United States (5) · Italy (4) · United Kingdom (4) · Bulgaria (3) · Germany (3) · Poland (3) · Spain (3) · Australia (2) · Belgium (2) · China (2) · Georgia (2) · Hungary (2) · Israel (2) · Latvia (2) · Romania (2)
Jennifer Kuo, MD (1) · John Kastelein, Professor (1) · Julie A. Sosa, MD, FACS (1)
2023 (2)